The Phase 3 SENTRY trial showed that combining selinexor (NEXPOVIO®) with ruxolitinib significantly improved spleen volume reduction by 49.8% at week 24 compared to 28% with ruxolitinib alone in myelofibrosis patients. This combination also showed a promising early overall survival benefit, reducing death risk by over 50%. While symptom improvement was similar to ruxolitinib alone, the spleen reduction was rapid, deep, and sustained, indicating potential disease modification. The treatment was generally well tolerated with manageable side effects. These results, presented at the EHA 2026 Congress, suggest a new therapeutic option for this rare blood cancer with limited current treatments.
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
